Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) and GeoVax Labs (NASDAQ:GOVX – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk and profitability.
Volatility & Risk
Mirum Pharmaceuticals has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 3.85, suggesting that its stock price is 285% more volatile than the S&P 500.
Insider and Institutional Ownership
6.1% of GeoVax Labs shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of GeoVax Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Mirum Pharmaceuticals and GeoVax Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mirum Pharmaceuticals | -134.75% | -97.25% | -12.59% |
| GeoVax Labs | N/A | -743.64% | -394.74% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Mirum Pharmaceuticals and GeoVax Labs, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mirum Pharmaceuticals | 1 | 0 | 13 | 1 | 2.93 |
| GeoVax Labs | 1 | 1 | 1 | 0 | 2.00 |
Mirum Pharmaceuticals presently has a consensus target price of $155.56, indicating a potential upside of 64.43%. GeoVax Labs has a consensus target price of $3,600.00, indicating a potential upside of 166,566.67%. Given GeoVax Labs’ higher possible upside, analysts plainly believe GeoVax Labs is more favorable than Mirum Pharmaceuticals.
Earnings & Valuation
This table compares Mirum Pharmaceuticals and GeoVax Labs”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mirum Pharmaceuticals | $670.78 million | 9.21 | -$23.36 million | ($15.47) | -6.12 |
| GeoVax Labs | $2.49 million | 6.39 | -$21.47 million | ($11.34) | -0.19 |
GeoVax Labs has lower revenue, but higher earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.
Summary
Mirum Pharmaceuticals beats GeoVax Labs on 8 of the 15 factors compared between the two stocks.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.
About GeoVax Labs
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s technology platform is based primarily on modified vaccinia Ankara (MVA) and virus-like particle (VLP) vaccine technologies, which are designed to generate broad and durable immune responses. GeoVax’s pipeline has included GEO-CM04S1, a multivalent COVID-19 vaccine candidate intended to address emerging coronavirus variants, as well as investigational vaccines for HIV, hemorrhagic fever viruses such as Ebola and Marburg, and other infectious diseases.
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
